Conferences

(UroToday.com) The 2024 ESMO annual meeting included a session highlighting urothelial carcinoma trials in progress, with Dr. Tian Zhang discussing STAR-EV, a phase I/II study of stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin for localized cisplatin ineligible, muscle invasive bladder cancer. Urothelial cancer is the 9^th most common cancer worldwide, with more than 610,000 people diagnosed per year. Muscle invasive bladder cancer needs more treatment options, and up to 50% of patients with muscle invasive bladder cancer cannot receive cisplatin-based chemotherapy. Definitive treatment of muscle invasive bladder cancer depends on neoadjuvant chemotherapy and surgery, or trimodality therapy with maximal resection followed by chemoradiation therapy.

(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Dag Rune Stormoen discussing the genetic profile in early and late stage urothelial tract cancer. Urothelial carcinoma is the 13^th most lethal cancer worldwide, with ongoing gaps in the knowledge of the mutational landscape in patients with advanced disease after multiple lines of prior treatment. This study presented at ESMO 2024 compared the genomic, transcriptomics, and targeted treatment options between metastatic urothelial carcinoma patients treated with multiple lines of therapy to newly diagnosed, untreated muscle invasive bladder cancer.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Christopher Sweeney discussing two abstracts including “CC-94676-PCA-001: Clinical activity of BMS-986365, a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with mCRPC” by Dr. Dana Rathkopf and “INSPIRE: Phase 2 trial of Nivolumab 3mg/kg and ipilimumab 1mg/kg in molecularly selected patients with mCRPC” by Dr. Niven Mehra. Dr. Sweeney started his discussant presentation by highlighting key features of metastatic CRPC treatment in 2024 and beyond:

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Guarionex DeCastro presented the results of a phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Deborah Mukherji discussing two abstracts including “RAPSON: Open-label, multicenter randomized trial of Radium-223 -> docetaxel versus docetaxel -> Radium-223 sequence in mCRPC with prospective biomarker evaluation” by Dr. Vincenza Conteduca and “Adding metformin to ADT for patients with mHSPC: Overall survival results from the multi-arm, multi-stage randomized platform trial STAMPEDE” by Dr. Silke Gillessen.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Niven Mehra discussing three abstracts including “Efficacy and safety of darolutamide plus ADT in patients with mHSPC from the phase 3 ARANOTE trial” by Dr. Fred Saad, “Prostate cancer efficacy results from a randomized phase 3 evaluation of transdermal estradiol versus LHRH agonists for androgen suppression in M0 prostate cancer” by Dr. Ruth Langley, and “Phenotypic and genomic characterization of de novo metastatic prostate cancer: an ancillary study of the PEACE-1 phase 3 trial” by Dr. Cedric Pobel.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 17^th was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Teresa Alonso Gordoa discussed systemic treatment options for the management of advanced renal cell carcinoma.

(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Chad Tang posed the question of whether there is a role for radiation therapy in advanced RCC. and moved on to discuss this important topic.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Fred Saad discussing the efficacy and safety of darolutamide plus ADT in patients with mHSPC from the phase 3 ARANOTE trial. In ARASENS, darolutamide + ADT + docetaxel significantly improved overall survival versus ADT + docetaxel in patients with mHSPC, and incidences of treatment-emergent adverse events were similar in both groups.¹ The phase 3 global ARANOTE trial (NCT04736199) compared darolutamide + ADT versus ADT in patients with mHSPC. At ESMO 2024, Dr. Saad presented the primary results of the trial.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Cédric Pobel discussing phenotypic and genomic characterization of de novo metastatic prostate cancer from the phase 3 PEACE-1 trial. Recently, the addition of abiraterone acetate + prednisone to docetaxel and ADT became a standard of care for metastatic castration-sensitive prostate cancer (mCSPC) following results of PEACE-1:¹

Reno, Nevada (UroToday.com) -- Results from the investigational pivotal Phase III ARANOTE trial demonstrated that NUBEQA^® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant and clinically meaningful improvement in radiological progression-free survival (rPFS) compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ¹ The results were presented today as a late-breaking oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, and published simultaneously in The Journal of Clinical Oncology.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Niven Mehra discussing nivolumab 3mg/kg and ipilimumab 1mg/kg in molecularly selected patients with mCRPC. Anti-PD1 immune checkpoint blockade is currently approved as monotherapy for mCRPC patients with a tumor mutational burden (TMB) of >10 mutations per megabase (mut/Mb) or mismatch repair deficiency.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Vincenza Conteduca discussing results from RAPSON, an open-label multicenter randomized trial of Radium-223 -> docetaxel versus docetaxel -> Radium-223 sequence in mCRPC with prospective biomarker evaluation. Defining the most effective treatment sequence between the α emitter Radium-223 and docetaxel is pivotal for optimizing bone-dominant mCRPC outcomes.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a session summarizing updates in the management of advanced renal cell carcinoma (RCC). Dr. Mir discussed the role of cytoreductive nephrectomy in the immunotherapy era.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Dana Rathkopf discussing the clinical activity of BMS-986365 (CC-94676) in heavily pretreated patients with mCRPC. The majority of mCRPC remains AR-dependent even if resistant to AR pathway inhibitors such as enzalutamide and abiraterone. BMS-986365 is a heterobifunctional, oral therapy designed to inhibit AR activity via a first-in-class dual mechanism of AR degradation and antagonism:

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Ruth Langley discussing efficacy results from a randomized phase 3 evaluation of transdermal estradiol versus luteinizing hormone-releasing hormone (LHRH) agonists for androgen suppression in M0 prostate cancer. Compared to LHRH agonists, transdermal estradiol lowers testosterone more rapidly, maintains bone mineral density, and improves metabolic outcomes and quality of life. Importantly, transdermal administration avoids the cardiovascular toxicity of oral estrogen.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Silke Gillessen discussing results from STAMPEDE assessing the addition of metformin to ADT for patients with mHSPC. ADT is standard of care in advanced prostate cancer, but it has metabolic adverse effects. Metformin is a widely used, well tolerated anti-diabetic agent. Several studies suggest metformin has anti-cancer activity in different malignancies, including prostate cancer. Dr. Gillessen and colleagues hypothesized that metformin also reduces the development of ADT-induced metabolic adverse effects, possibly improving overall survival via these mechanisms.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a proffered paper session for prostate cancer. Dr. Rana McKay delivered the discussant session for CONTACT-02 and the post-hoc analysis of STAMPEDE Docetaxel assessing Decipher® as a potential predictive biomarker for overall survival in metastatic hormone sensitive prostate cancer (mHSPC) patients receiving docetaxel doublet therapy.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a proffered paper session for prostate cancer. Dr. Neeraj Agarwal presented the final overall survival results of CONTACT-02, a phase III randomized trial of cabozantinib plus atezolizumab versus a 2^nd novel hormonal therapy (NHT) in patients with metastatic castrate-resistant prostate cancer (mCRPC).

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a proffered paper session for prostate cancer. Dr. Emily Grist presented the results of an ancillary study of the STAMPEDE Docetaxel trial evaluating the genomic classifier Decipher® mRNA score for predicting a survival benefit with docetaxel doublet therapy intensification for metastatic hormone sensitive prostate cancer (mHSPC) patients.